CASP8AP2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.59629998108812E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
8.0379999999991E-05 |
Normal-vs-Stage2 |
6.024400E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
2.376400E-02 |
Stage1-vs-Stage2 |
5.822800E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.497000E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
6.936800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
3.86830000254079E-08 |
Normal-vs-AfricanAmerican |
1.867560E-01 |
Normal-vs-Asian |
7.750400E-02 |
Caucasian-vs-AfricanAmerican |
1.393570E-02 |
Caucasian-vs-Asian |
2.647600E-01 |
AfricanAmerican-vs-Asian |
3.168000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
5.51540000000017E-05 |
Normal-vs-Female |
3.78890000000132E-05 |
Male-vs-Female |
8.046000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.626010E-02 |
Normal-vs-Extreme_Weight |
1.046410E-04 |
Normal-vs-Obese |
3.963200E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
9.993800E-01 |
Normal_Weight-vs-Obese |
3.689000E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
2.358400E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.237410E-01 |
Normal-vs-Age(41-60Yrs) |
5.861200E-03 |
Normal-vs-Age(61-80Yrs) |
2.81140000002456E-06 |
Normal-vs-Age(81-100Yrs) |
4.42659999766448E-08 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.314800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.266800E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.501000E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.623000E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.291600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.414000E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
4.204600E-01 |
Normal-vs-Grade 3 |
1.319410E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
5.765000E-01 |
Grade 2-vs-Grade 4 |
4.204600E-01 |
Grade 3-vs-Grade 4 |
1.319410E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.54980000000027E-06 |
Normal-vs-N1 |
1.960280E-02 |
N0-vs-N1 |
3.847200E-01 |
|
|